News

Radient Pharmaceuticals, through its wholly-owned subsidiary, AMDL Diagnostics, has entered into an exclusive five-year marketing and distribution agreement with Grifols USA, a healthcare products manufacturer and distributor. Under

CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world’s first patented triple-combination cardiovascular polypill. Reportedly, CardioPharma collected data on thousands of patients

Medtronic has launched Captivia Delivery System for the Valiant Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta. The system features

Labopharm has reported that its wholly-owned subsidiary, Labopharm Europe has completed a distribution and supply agreement with Grunenthal for its twice-daily tramadol acetaminophen formulation. Under the terms of

Antisoma, following discussions with FDA and trial investigators, plans to amend the primary endpoint in the ACCEDE study of AS1413. The ACCEDE study is an ongoing randomised, controlled

Lpath has reported positive results of its single-dose phase 1 clinical trial of isonep in wet-AMD patients. The result suggested that isonep met its primary endpoint of being

IMS Health estimates that the global pharmaceutical market in 2010 will grow 4-6% on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the US

APP Pharmaceuticals, a wholly-owned subsidiary of Fresenius Kabi Pharmaceuticals (Kabi), has received approval from the FDA to market Sumatriptan Succinate Injection, USP, in two dosage strengths. Sumatriptan Succinate

MacuCLEAR and Mystic Pharmaceuticals have announced preliminary results of phase Ib clinical trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). According